In a report released yesterday, Research Report), with a price target of $150.00. The company’s shares closed yesterday at $151.53.
Mason CFA covers the Technology sector, focusing on stocks such as Cognex, Roper Technologies, and Zebra Tech. According to TipRanks, Mason CFA has an average return of -9.2% and a 24.62% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novanta with a $129.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $184.44 and a one-year low of $110.84. Currently, Novanta has an average volume of 309K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novanta, Inc. engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products. The Vision segment a range of medical grade technologies, including medical insufflators, pumps and related disposables; surgical displays and operating room integration technologies; optical data collection and machine vision technologies; radio frequency identification technologies; thermal printers; spectrometry technologies; and embedded touch screen solutions. The Precision Motion segment includes optical encoders, precision motor and motion control technology, air bearing spindles and precision machined components to customers. The company was founded in 1968 and is headquartered in Bedford, MA.
Read More on NOVT:
- Cerence (CRNC) Receives a Hold from Robert W. Baird
- Robert W. Baird Remains a Buy on Cellectis SA (CLLS)
- Robert W. Baird Sticks to Their Hold Rating for Vir Biotechnology (VIR)
- Robert W. Baird Reaffirms Their Buy Rating on Camden Property (CPT)
- Capri Holdings (CPRI) Receives a Buy from Robert W. Baird
